{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T18:51:24Z","timestamp":1785783084310,"version":"3.56.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpurol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pediatric Urology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jpurol.2025.01.016","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T04:05:27Z","timestamp":1737691527000},"page":"1233-1238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mirabegron as part of combination therapy for treatment refractory neurogenic bladder in pediatric patients with spina bifida"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4772-0219","authenticated-orcid":false,"given":"Tyler","family":"Gaines","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8958-939X","authenticated-orcid":false,"given":"Paul","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9386-6855","authenticated-orcid":false,"given":"Katherine","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Van Batavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Zderic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Daugherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"VanderBrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2783-7754","authenticated-orcid":false,"given":"Christopher","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jpurol.2025.01.016_bib1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jpurol.2013.02.015","article-title":"Single centre experience: long term outcomes in spina bifida patients","volume":"9","author":"Malakounides","year":"2013","journal-title":"J Pediatr Urol"},{"issue":"2","key":"10.1016\/j.jpurol.2025.01.016_bib2","doi-asserted-by":"crossref","first-page":"195.e1","DOI":"10.1016\/j.jpurol.2022.12.013","article-title":"Age-based risk of end-stage kidney disease in patients with myelomeningocele","volume":"19","author":"Adams","year":"2023","journal-title":"J Pediatr Urol"},{"issue":"6","key":"10.1016\/j.jpurol.2025.01.016_bib3","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00467-008-0780-7","article-title":"Treatment of the neurogenic bladder in spina bifida","volume":"23","author":"de Jong","year":"2008","journal-title":"Pediatr Nephrol"},{"issue":"5\u20136","key":"10.1016\/j.jpurol.2025.01.016_bib4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.5489\/cuaj.1362","article-title":"Double anticholinergic therapy for refractory neurogenic and nonneurogenic detrusor overactivity in children: long-term results of a prospective open-label study","volume":"8","author":"Nadeau","year":"2014","journal-title":"Can Urol Assoc J."},{"issue":"4","key":"10.1016\/j.jpurol.2025.01.016_bib5","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/S0022-5347(01)66914-3","article-title":"The long-term urological response of neonates with myelodysplasia treated proactively with intermittent catheterization and anticholinergic therapy","volume":"154","author":"Edelstein","year":"1995","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.jpurol.2025.01.016_bib6","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/nau.24778","article-title":"Onabotulinumtoxin A (Botox): a reasonable alternative for refractory neurogenic bladder dysfunction in children and young adults","volume":"40","author":"Softness","year":"2021","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"10.1016\/j.jpurol.2025.01.016_bib7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/JU.0000000000000540","article-title":"Urodynamic outcomes in children after single and multiple injections for overactive and low compliance neurogenic bladder treated with abobotulinum toxin","volume":"203","author":"Naqvi","year":"2020","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.jpurol.2025.01.016_bib8","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/JU.0000000000002235","article-title":"The AUA\/SUFU guideline on adult neurogenic lower urinary tract dysfunction: diagnosis and evaluation","volume":"206","author":"Ginsberg","year":"2021","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.jpurol.2025.01.016_bib9","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1002\/nau.24657","article-title":"Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: an open-label, phase 3, dose-titration study","volume":"40","author":"Baka-Ostrowska","year":"2021","journal-title":"Neurourol Urodyn"},{"issue":"8","key":"10.1016\/j.jpurol.2025.01.016_bib10","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s00345-018-2576-0","article-title":"Efficacy and safety of mirabegron, a \u03b23-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study","volume":"37","author":"Park","year":"2019","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.jpurol.2025.01.016_bib11","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jpurol.2021.04.019","article-title":"Urodynamic characteristics of neurogenic bladder in newborns with myelomeningocele and refinement of the definition of bladder hostility: findings from the UMPIRE multi-center study","volume":"17","author":"Tanaka","year":"2021","journal-title":"J Pediatr Urol"},{"issue":"1","key":"10.1016\/j.jpurol.2025.01.016_bib12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-3468(91)90426-T","article-title":"Bladder capacity in infants","volume":"26","author":"Fairhurst","year":"1991","journal-title":"J Pediatr Surg"},{"issue":"2","key":"10.1016\/j.jpurol.2025.01.016_bib13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0022-5347(17)52091-1","article-title":"Bladder capacity (ounces) equals age (years) plus 2 predicts normal bladder capacity and aids in diagnosis of abnormal voiding patterns","volume":"129","author":"Berger","year":"1983","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.jpurol.2025.01.016_bib14","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/nau.22783","article-title":"International Children's Continence Society standardization report on urodynamic studies of the lower urinary tract in children","volume":"34","author":"Bauer","year":"2015","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"10.1016\/j.jpurol.2025.01.016_bib15","doi-asserted-by":"crossref","first-page":"753.e1","DOI":"10.1016\/j.jpurol.2023.08.015","article-title":"Long-term beneficial effects of mirabegron in pediatric patients with therapy-refractory neurogenic lower urinary tract dysfunction","volume":"19","author":"van Veen","year":"2023","journal-title":"J Pediatr Urol"},{"issue":"5","key":"10.1016\/j.jpurol.2025.01.016_bib16","doi-asserted-by":"crossref","first-page":"655.sae1","DOI":"10.1016\/j.jpurol.2020.07.020","article-title":"Efficacy and safety of Mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction","volume":"16","author":"Sager","year":"2020","journal-title":"J Pediatr Urol"},{"key":"10.1016\/j.jpurol.2025.01.016_bib17","doi-asserted-by":"crossref","unstructured":"Herschorn S, Chapple CR, Abrams P et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int2017; 120: 562\u2013575.","DOI":"10.1111\/bju.13882"},{"issue":"6","key":"10.1016\/j.jpurol.2025.01.016_bib18","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/JU.0000000000000751","article-title":"Additional surgeries after bladder augmentation in patients with spina bifida in the 21st century","volume":"203","author":"Szymanski","year":"2020","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.jpurol.2025.01.016_bib19","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.juro.2017.12.051","article-title":"Interrater reliability in interpretation of neuropathic pediatric urodynamic tracings: an expanded multicenter study","volume":"199","author":"Dudley","year":"2018","journal-title":"J Urol"}],"container-title":["Journal of Pediatric Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147751312500018X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147751312500018X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T03:25:58Z","timestamp":1760066758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147751312500018X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S147751312500018X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpurol.2025.01.016","relation":{},"ISSN":["1477-5131"],"issn-type":[{"value":"1477-5131","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mirabegron as part of combination therapy for treatment refractory neurogenic bladder in pediatric patients with spina bifida","name":"articletitle","label":"Article Title"},{"value":"Journal of Pediatric Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpurol.2025.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}